Gossamer Bio (NASDAQ:GOSS) Rating Reiterated by The Goldman Sachs Group

Gossamer Bio (NASDAQ:GOSSGet Free Report)‘s stock had its “buy” rating restated by stock analysts at The Goldman Sachs Group in a report issued on Monday, Benzinga reports. They presently have a $8.00 price target on the stock.

Several other research analysts have also weighed in on the company. Piper Sandler reissued an “overweight” rating and issued a $15.00 price objective on shares of Gossamer Bio in a research report on Wednesday, March 27th. Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a research report on Wednesday, May 8th. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research report on Monday, May 20th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, Gossamer Bio currently has an average rating of “Moderate Buy” and an average price target of $7.65.

Read Our Latest Research Report on Gossamer Bio

Gossamer Bio Stock Up 4.3 %

Shares of NASDAQ:GOSS opened at $0.54 on Monday. The business has a fifty day simple moving average of $0.68 and a 200 day simple moving average of $0.93. Gossamer Bio has a 12-month low of $0.45 and a 12-month high of $1.88. The company has a quick ratio of 7.13, a current ratio of 7.13 and a debt-to-equity ratio of 7.37. The firm has a market cap of $122.70 million, a P/E ratio of -0.51 and a beta of 1.91.

Gossamer Bio (NASDAQ:GOSSGet Free Report) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.19) earnings per share for the quarter, hitting the consensus estimate of ($0.19). Analysts predict that Gossamer Bio will post -0.35 earnings per share for the current year.

Insider Activity at Gossamer Bio

In related news, CEO Faheem Hasnain sold 23,172 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $1.16, for a total value of $26,879.52. Following the completion of the sale, the chief executive officer now directly owns 120,293 shares of the company’s stock, valued at approximately $139,539.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Gossamer Bio

Hedge funds have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC acquired a new position in Gossamer Bio during the 1st quarter valued at about $29,000. SG Americas Securities LLC acquired a new position in Gossamer Bio during the 1st quarter valued at about $34,000. Financial Advocates Investment Management boosted its stake in Gossamer Bio by 35.0% during the 4th quarter. Financial Advocates Investment Management now owns 98,350 shares of the company’s stock valued at $90,000 after purchasing an additional 25,500 shares during the last quarter. Citigroup Inc. boosted its stake in Gossamer Bio by 9,916.9% during the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock valued at $164,000 after purchasing an additional 194,768 shares during the last quarter. Finally, Kynam Capital Management LP acquired a new position in Gossamer Bio during the 3rd quarter valued at about $208,000. Institutional investors and hedge funds own 81.23% of the company’s stock.

Gossamer Bio Company Profile

(Get Free Report)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Recommended Stories

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.